Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
NCT ID: NCT02258867
Last Updated: 2015-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
4 participants
INTERVENTIONAL
2014-11-30
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Solution for subcutaneous injection
Gevokizumab
Gevokizumab
Solution for subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Solution for subcutaneous injection
Gevokizumab
Solution for subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a documented history of active uveitis with or without retinal vasculitis within the past 12 months
* Best corrected visual acuity (BCVA) \>= 20 ETDRS letters in both eyes at baseline
* Effective contraceptive measures
Exclusion Criteria
* End stage ocular disease
* History of allergic or anaphylactic reactions to monoclonal antibodies
* Active tuberculosis disease
* History of recurrent infection or predisposition to infection; active ocular infection
* Pregnant or nursing women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XOMA (US) LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santa Ana, California, United States
Chicago, Illinois, United States
Ellsworth, Maine, United States
Cambridge, Massachusetts, United States
Royal Oak, Michigan, United States
Winston-Salem, North Carolina, United States
Fargo, North Dakota, United States
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X052133
Identifier Type: -
Identifier Source: org_study_id